Workflow
药物临床试验质量管理规范(GCP)
icon
Search documents
观众报名!临床试验质量管理规范分论坛
思宇MedTech· 2025-10-25 10:09
规范化试验,保障临床价值 随着医美产品研发进入快速发展阶段,临床试验已成为创新成果进入市场的关键环 节。如何确保试验设计科学、执行规范、数据可靠?《药物临床试验质量管理规范 (GCP)》为行业提供了统一的标准。 在医美领域,临床试验的复杂性和合规要求不断提升。本届大会特别设立 "临床试 验质量管理规范分论坛" ,系统解析GCP核心要点,探讨医美相关试验的实施与监 管要求,推动多方协作的高质量发展。 第二届论坛回顾: 概念验证驱动创新,医工交叉赋能医美:第二届八大处整形美容产 业论坛圆满召开 时间: 2025年10月31日 – 11月2日 地点: 北京市银保国际会议中心 主办单位: 北 京八大处整形医疗科技集团有限公司 北京医疗整形美容业协会 一、临床试验质量管理规范 分论坛信息 时间 : 2025年11月2日(星期日)9:00-12:10 地点: 北京市银保国际会议中心 二层第八会议室 主办单位 : 中国医学科学院整形外科医院临床试验机构、八大处整形医学概念验证中心 议程 : 主持人:车宇航 中国医学科学院整形外科医院临床试验机构办公室副主任 9:00-9:10 领导 致 辞 中国医学科学院整形外科医院 皮肤 ...
报名开启!临床试验质量管理规范|第三届八大处整形美容产业论坛分论坛
思宇MedTech· 2025-10-24 11:08
Core Viewpoint - The article emphasizes the importance of standardized clinical trials in the medical aesthetics industry, highlighting the need for scientific design, regulatory compliance, and reliable data to ensure the clinical value of innovative products [2]. Group 1: Clinical Trial Quality Management - The "Good Clinical Practice (GCP)" provides a unified standard for the industry, addressing the increasing complexity and compliance requirements of clinical trials in the medical aesthetics field [2]. - A special forum on "Clinical Trial Quality Management" was established to analyze GCP core points and discuss the implementation and regulatory requirements of medical aesthetics-related trials [2]. Group 2: Forum Details - The second forum on the medical aesthetics industry was successfully held, with the next forum scheduled for October 31 to November 2, 2025, at the Beijing International Conference Center [4]. - The agenda for the Clinical Trial Quality Management forum includes various presentations from experts in the field, covering common issues in clinical trials, high-quality research design, collaboration for effective trials, and ethical review from a legal perspective [5]. Group 3: Participants - The forum is expected to attract a diverse group of participants, including senior lawyers, medical device and aesthetics company representatives, clinical doctors, researchers, investment institution representatives, and regulatory experts [7].